DE69638073D1
(de)
*
|
1996-09-04 |
2009-12-24 |
Intertrust Tech Corp |
Zuverlässige Infrastrukturhilfssysteme, Verfahren und Techniken für sicheren elektronischen Handel, elektronische Transaktionen, Handelsablaufsteuerung und Automatisierung, verteilte Verarbeitung und Rechteverwaltung
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
CA2395593C
(en)
|
1999-12-24 |
2011-08-02 |
Aventis Pharma Limited |
Azaindoles
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
ES2242771T5
(es)
*
|
2000-09-15 |
2011-10-14 |
Vertex Pharmaceuticals Incorporated |
Compuestos de pirazol útiles como inhibidores de proteína quinasas.
|
AU2002222293A1
(en)
*
|
2000-12-19 |
2002-07-01 |
Smithkline Beecham P.L.C. |
Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
|
ATE327989T1
(de)
*
|
2000-12-21 |
2006-06-15 |
Vertex Pharma |
Pyrazolverbindungen als protein-kinase- inhibitoren
|
KR100847169B1
(ko)
|
2000-12-21 |
2008-07-17 |
글락소 그룹 리미티드 |
혈관형성 조절제로서의 피리미딘아민
|
WO2002079163A1
(en)
*
|
2001-03-30 |
2002-10-10 |
Smithkline Beecham Corporation |
Aminopyridine derivatives as estrogen receptor modulators
|
EP1404669A2
(de)
*
|
2001-05-16 |
2004-04-07 |
Vertex Pharmaceuticals Incorporated |
Heterocyclisch substituierte pyrazole als inhibitoren von src und anderen protein kinasen
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
WO2003018563A1
(en)
|
2001-08-31 |
2003-03-06 |
Northwestern University |
Anti-inflammatory and protein kinase inhibitor composition and method of use
|
WO2003030909A1
(en)
*
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
CZ2004359A3
(cs)
|
2001-09-26 |
2004-09-15 |
Pharmacia Italia S.P.A. |
Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty
|
TWI330183B
(de)
|
2001-10-22 |
2010-09-11 |
Eisai R&D Man Co Ltd |
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
CA2469316A1
(en)
|
2001-12-07 |
2003-06-19 |
Vertex Pharmaceuticals, Inc. |
Pyrimidine-based compounds useful as gsk-3 inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
ATE323706T1
(de)
|
2001-12-17 |
2006-05-15 |
Smithkline Beecham Corp |
Pyrazolopyridazinderivate
|
AU2002361846A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
US20030158195A1
(en)
|
2001-12-21 |
2003-08-21 |
Cywin Charles L. |
1,6 naphthyridines useful as inhibitors of SYK kinase
|
KR20040085151A
(ko)
|
2002-01-17 |
2004-10-07 |
뉴로젠 코포레이션 |
캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
EP2322521B1
(de)
*
|
2002-02-06 |
2013-09-04 |
Vertex Pharmaceuticals, Inc. |
Heteroaryl-Verbindungen und Ihre Anwendung als GSK-3-Hemmer
|
EP1485100B1
(de)
*
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazine als proteinkinasehemmer
|
US7179826B2
(en)
|
2002-03-15 |
2007-02-20 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
DE60332604D1
(de)
*
|
2002-03-15 |
2010-07-01 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
IL163737A0
(en)
*
|
2002-04-05 |
2005-12-18 |
Boehringer Ingelheim Pharma |
Method of treating mucus hypersecretion
|
AU2003231232A1
(en)
|
2002-05-01 |
2003-11-17 |
Vertex Pharmaceuticals Incorporated |
Crystal structure of aurora-2 protein and binding pockets thereof
|
ATE493987T1
(de)
|
2002-05-22 |
2011-01-15 |
Amgen Inc |
Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
|
WO2003104230A1
(ja)
*
|
2002-06-07 |
2003-12-18 |
協和醱酵工業株式会社 |
二環性ピリミジン誘導体
|
WO2003106455A1
(en)
|
2002-06-14 |
2003-12-24 |
Applied Research Systems Ars Holding N.V. |
Azole methylidene cyanide derivatives and their use as protein kinase modulators
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
AU2003249369A1
(en)
|
2002-06-21 |
2004-01-06 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
EP1534716B1
(de)
*
|
2002-07-17 |
2008-04-23 |
Pfizer Italia S.r.l. |
Heterobicyclische pyrazolderivate als kinaseinhibitoren
|
EP1575506A4
(de)
*
|
2002-07-25 |
2008-04-23 |
Scios Inc |
Verfahren zur verbesserung der lungenfunktion mit tgf-beta hemmern
|
BR0313059B8
(pt)
|
2002-07-29 |
2021-07-27 |
Rigel Pharmaceuticals |
composto, e, composição farmacêutica
|
EP1739087A1
(de)
*
|
2002-08-02 |
2007-01-03 |
Vertex Pharmaceuticals Incorporated |
Pyrazolenthaltende Zusammensetzungen und ihre Verwendung als Gsk-3 Inhibitoren
|
KR20050032105A
(ko)
*
|
2002-08-02 |
2005-04-06 |
버텍스 파마슈티칼스 인코포레이티드 |
Gsk-3의 억제제로서 유용한 피라졸 조성물
|
DE60325865D1
(de)
*
|
2002-08-13 |
2009-03-05 |
Merck Sharp & Dohme |
Phenylpyridazin derivative als liganden für gaba-rezeptoren
|
KR20050042478A
(ko)
|
2002-08-14 |
2005-05-09 |
버텍스 파마슈티칼스 인코포레이티드 |
프로테인 키나아제 억제제 및 이의 용도
|
MXPA05001807A
(es)
|
2002-09-05 |
2005-04-19 |
Aventis Pharma Sa |
Nuevos derivados de aminoindazol utilizados como medicamentos y composiciones farmaceuticas que los contienen.
|
FR2844267B1
(fr)
*
|
2002-09-05 |
2008-02-15 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
UA80295C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
WO2004024159A1
(en)
*
|
2002-09-10 |
2004-03-25 |
Scios Inc. |
INHIBITORS OF TFGβ
|
US7312227B2
(en)
|
2002-11-01 |
2007-12-25 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of JAK and other protein kinases
|
JP2006508107A
(ja)
|
2002-11-05 |
2006-03-09 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Jakおよび他のプロテインキナーゼのインヒビターとして有用な化合物
|
ATE527250T1
(de)
|
2002-11-21 |
2011-10-15 |
Novartis Ag |
2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
|
CN1735607B
(zh)
*
|
2002-11-21 |
2010-06-09 |
诺华疫苗和诊断公司 |
2,4,6-三取代的嘧啶作为磷脂酰肌醇(pi)3-激酶抑制剂及其在治疗癌症中的应用
|
JP4666256B2
(ja)
*
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
FR2848554A1
(fr)
*
|
2002-12-12 |
2004-06-18 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
CA2507948A1
(fr)
|
2002-12-12 |
2004-07-29 |
Aventis Pharma S.A. |
Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
|
CA2509239A1
(en)
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
US7601718B2
(en)
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
WO2004087056A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Scios Inc. |
BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
|
US7763627B2
(en)
*
|
2003-04-09 |
2010-07-27 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
US7638530B2
(en)
*
|
2003-04-24 |
2009-12-29 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
WO2004096808A1
(en)
*
|
2003-04-28 |
2004-11-11 |
De Novo Pharmaceuticals Limited |
Triazine compounds and their use
|
CA2528834A1
(en)
*
|
2003-06-13 |
2005-02-10 |
Arena Pharmaceuticals, Inc. |
5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
|
JP2007524615A
(ja)
*
|
2003-06-20 |
2007-08-30 |
コーリー ファーマシューティカル ゲーエムベーハー |
低分子トール様レセプター(tlr)アンタゴニスト
|
TW200510373A
(en)
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
US7329664B2
(en)
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
NZ544756A
(en)
|
2003-07-22 |
2009-09-25 |
Astex Therapeutics Ltd |
3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
PT1656372E
(pt)
|
2003-07-30 |
2013-06-27 |
Rigel Pharmaceuticals Inc |
Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
|
TW200521119A
(en)
*
|
2003-08-05 |
2005-07-01 |
Vertex Pharma |
Compositions useful as inhibitors of voltage-gated ion channels
|
AU2004263148B2
(en)
*
|
2003-08-06 |
2008-08-21 |
Vertex Pharmaceuticals, Incorporated |
Aminotriazole compounds useful as inhibitors of protein kinases
|
AU2004276341B2
(en)
*
|
2003-09-23 |
2011-04-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyrrole derivatives as protein kinase inhibitors
|
GB0323137D0
(en)
|
2003-10-03 |
2003-11-05 |
Chang Lisa C W |
2,4,6- Trisubstituted pyrimidines and their different uses
|
US7579349B2
(en)
*
|
2003-10-17 |
2009-08-25 |
Astrazeneca Ab |
4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
|
WO2005047268A2
(en)
*
|
2003-11-10 |
2005-05-26 |
X-Ceptor Therapeutics, Inc. |
Substituted pyrimidine compositions and methods of use
|
AU2004289304A1
(en)
*
|
2003-11-10 |
2005-05-26 |
Synta Pharmaceuticals, Corp. |
Pyridine compounds
|
CN102127056B
(zh)
*
|
2003-12-03 |
2013-08-21 |
Ym生物科学澳大利亚私人有限公司 |
微管蛋白抑制剂
|
AU2004297235A1
(en)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
CA2548009A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Naphthyridine derivatives and their use as modulators of muscarinic receptors
|
JP2007514759A
(ja)
*
|
2003-12-19 |
2007-06-07 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
TW200530235A
(en)
|
2003-12-24 |
2005-09-16 |
Renovis Inc |
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
|
WO2005070891A2
(en)
|
2004-01-23 |
2005-08-04 |
Amgen Inc |
Compounds and methods of use
|
WO2005073224A2
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
US7534798B2
(en)
|
2004-02-11 |
2009-05-19 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
EP1742936A2
(de)
|
2004-04-13 |
2007-01-17 |
Icagen, Inc. |
Polycyclische pyridine als kaliumionenkanalmodulatoren
|
JP2007533753A
(ja)
*
|
2004-04-23 |
2007-11-22 |
タケダ サン ディエゴ インコーポレイテッド |
インドール誘導体及びキナーゼ阻害剤としてのその使用
|
US7793137B2
(en)
|
2004-10-07 |
2010-09-07 |
Cisco Technology, Inc. |
Redundant power and data in a wired data telecommunincations network
|
ES2391577T3
(es)
|
2004-05-14 |
2012-11-27 |
Millennium Pharmaceuticals, Inc. |
Los compuestos y métodos para inhibir la progresión mitótica mediante la inhibición de la aurora quinasa
|
EP1604988A1
(de)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinonderivate, Methoden, um selbige herzustellen, und ihre Verwendung als Pharmazeutika
|
EP1598348A1
(de)
|
2004-05-18 |
2005-11-23 |
Aventis Pharma Deutschland GmbH |
Pyridazinonderivate als CDK2-Inhibitoren
|
DE102004028862A1
(de)
*
|
2004-06-15 |
2005-12-29 |
Merck Patent Gmbh |
3-Aminoindazole
|
GB0415364D0
(en)
*
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
US20080261821A1
(en)
*
|
2004-07-21 |
2008-10-23 |
The Regents Of Te University Of California |
Mechanism-Based Crosslinkers
|
US7550598B2
(en)
*
|
2004-08-18 |
2009-06-23 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
US7858813B2
(en)
|
2004-08-19 |
2010-12-28 |
Dsm Ip Assets B.V. |
Process for the rectification of mixtures of high-boiling air-and/or temperature-sensitive useful products
|
GB0419416D0
(en)
*
|
2004-09-01 |
2004-10-06 |
Inst Of Ex Botany Ascr |
4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
|
CA2579143A1
(en)
|
2004-09-13 |
2006-03-23 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
CA2581454A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyrimidine compounds, process for their preparation and compositions containing them
|
TW200624431A
(en)
|
2004-09-24 |
2006-07-16 |
Hoffmann La Roche |
Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
WO2006035061A1
(en)
|
2004-09-30 |
2006-04-06 |
Tibotec Pharmaceuticals Ltd. |
Hcv inhibiting bi-cyclic pyrimidines
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
US7713973B2
(en)
|
2004-10-15 |
2010-05-11 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
TW200621257A
(en)
*
|
2004-10-20 |
2006-07-01 |
Astellas Pharma Inc |
Pyrimidine derivative fused with nonaromatic ring
|
EP2592075B1
(de)
|
2004-11-02 |
2015-04-29 |
Northwestern University |
Pyridazinverbindungen zur behandlung von entzündlichen erkrankungen
|
CA2589102C
(en)
|
2004-11-02 |
2013-08-13 |
Northwestern University |
Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
|
KR20070086188A
(ko)
|
2004-11-17 |
2007-08-27 |
미카나 테라퓨틱스, 인크. |
키나제 억제제
|
US7557207B2
(en)
|
2004-11-24 |
2009-07-07 |
Rigel Pharmaceuticals, Inc. |
Spiro 2,4-pyrimidinediamine compounds and their uses
|
EP1827434B1
(de)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Chinolin- und chinazolinanaloge und deren verwendung als medikamente zur krebsbehandlung
|
US20060128710A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
JP2008525422A
(ja)
*
|
2004-12-23 |
2008-07-17 |
ファイザー・プロダクツ・インク |
抗癌剤として有用な複素芳香族誘導体
|
WO2006074057A2
(en)
*
|
2004-12-30 |
2006-07-13 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
RU2416616C2
(ru)
|
2005-01-19 |
2011-04-20 |
Райджел Фармасьютикалз, Инк. |
Пролекарства соединений 2,4-пиримидиндиамина и их применения
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
CA2595514C
(en)
*
|
2005-01-26 |
2012-06-12 |
Schering Corporation |
Kinase inhibitors
|
SI2383268T1
(sl)
*
|
2005-02-04 |
2016-02-29 |
Astrazeneca Ab |
Derivati pirazolilaminopiridina uporabni kot kinazni inhibitorji
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
DK1853588T3
(da)
|
2005-02-16 |
2008-09-15 |
Astrazeneca Ab |
Kemiske forbindelser
|
EP1863797A1
(de)
*
|
2005-03-23 |
2007-12-12 |
AstraZeneca AB |
2-azetidinyl-4-(lh-pyrazol-3-ylamino)pyrimidine als inhibitoren der aktivität des rezeptors für den insulin-like growth factor-i
|
US7402596B2
(en)
|
2005-03-24 |
2008-07-22 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
WO2006100310A1
(en)
|
2005-03-25 |
2006-09-28 |
Tibotec Pharmaceuticals Ltd |
Heterobicylic inhibitors of hcv
|
ES2310406T3
(es)
*
|
2005-04-05 |
2009-01-01 |
Astrazeneca Ab |
Derivados de pirimidina para uso como agentes anticancerosos.
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
CA2603204A1
(en)
|
2005-04-14 |
2006-10-19 |
F. Hoffmann-La Roche Ag |
Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
ES2545382T3
(es)
|
2005-04-28 |
2015-09-10 |
Mitsubishi Tanabe Pharma Corporation |
Derivado de cianopiridina y su uso como medicamento
|
EP1885454A2
(de)
|
2005-05-04 |
2008-02-13 |
DeveloGen Aktiengesellschaft |
Verwendung von gsk-3-hemmern zur prävention und behandlung von pankreatischen autoimmunkrankheiten
|
WO2006119504A2
(en)
*
|
2005-05-04 |
2006-11-09 |
Renovis, Inc. |
Fused heterocyclic compounds, and compositions and uses thereof
|
CN101218229A
(zh)
*
|
2005-05-05 |
2008-07-09 |
阿斯利康(瑞典)有限公司 |
吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
EP1899323A2
(de)
|
2005-05-16 |
2008-03-19 |
AstraZeneca AB |
Als tyrosinkinaseinhibitoren geeignete pyrazolylaminopyrimidinderivate
|
JP2008543888A
(ja)
|
2005-06-24 |
2008-12-04 |
ギリアード サイエンシーズ, インコーポレイテッド |
ピリド(3,2−d)ピリミジン、およびC型肝炎を治療するのに有用な医薬組成物
|
ES2270715B1
(es)
|
2005-07-29 |
2008-04-01 |
Laboratorios Almirall S.A. |
Nuevos derivados de pirazina.
|
CA2619517A1
(en)
*
|
2005-08-18 |
2007-02-22 |
Michael Mortimore |
Pyrazine kinase inhibitors
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
EP2275096A3
(de)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenese durch modulation des Muscarinrezeptors
|
EP2258359A3
(de)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
CN101316587B
(zh)
*
|
2005-09-30 |
2013-04-03 |
迈卡纳治疗股份有限公司 |
取代的吡唑化合物
|
BRPI0616630B8
(pt)
*
|
2005-09-30 |
2021-05-25 |
Miikana Therapeutics Inc |
compostos de pirazol substituídos
|
ES2274712B1
(es)
|
2005-10-06 |
2008-03-01 |
Laboratorios Almirall S.A. |
Nuevos derivados imidazopiridina.
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
GB0520657D0
(en)
*
|
2005-10-11 |
2005-11-16 |
Ludwig Inst Cancer Res |
Pharmaceutical compounds
|
EP1940389A2
(de)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation von neurogenese durch pde-hemmung
|
PL1945631T3
(pl)
|
2005-10-28 |
2012-12-31 |
Astrazeneca Ab |
Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka
|
EP1942879A1
(de)
|
2005-10-31 |
2008-07-16 |
Braincells, Inc. |
Gaba-rezeptor-vermittelte modulation von neurogenese
|
RU2423361C2
(ru)
*
|
2005-11-03 |
2011-07-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Аминопиримидины в качестве ингибиторов киназ
|
ZA200803887B
(en)
|
2005-11-08 |
2009-12-30 |
Vertex Pharma |
Heterocyclic modulators of ATP-Binding Cassette transporters
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
US7572809B2
(en)
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
EP1966152A2
(de)
*
|
2005-12-20 |
2008-09-10 |
Takeda Pharmaceutical Company Limited |
Glucokinase-aktivatoren
|
EP1973911B1
(de)
|
2006-01-17 |
2016-01-13 |
Vertex Pharmaceuticals Incorporated |
Zur behandlung von (unter anderem) proliferativen, kardiologischen, neurodegenerativen, autoimmun- oder entzündlichen erkrankungen geeignete azaindole
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
DE602007009932D1
(de)
|
2006-02-16 |
2010-12-02 |
Schering Corp |
Pyrrolidin-derivate als erk-hemmer
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
CA2643199A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
PE20080145A1
(es)
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
Tetrahidro-pirimidoazepinas como moduladores de trpv1
|
AU2007235237B2
(en)
*
|
2006-04-11 |
2011-08-18 |
Vertex Pharmaceuticals Incorporated |
Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
|
US8158627B2
(en)
|
2006-04-28 |
2012-04-17 |
Northwestern University |
Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
WO2007134077A2
(en)
*
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
CA2656003C
(en)
|
2006-06-27 |
2014-03-25 |
Tsuneo Yasuma |
Fused cyclic compounds
|
WO2008001070A1
(en)
*
|
2006-06-30 |
2008-01-03 |
Astrazeneca Ab |
Pyrimidine derivatives useful in the treatment of cancer
|
AU2007269540B2
(en)
*
|
2006-07-05 |
2013-06-27 |
Exelixis, Inc. |
Methods of using IGF1R and Abl kinase modulators
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
US8003651B2
(en)
*
|
2006-07-06 |
2011-08-23 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
UA95641C2
(en)
*
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
US8338435B2
(en)
|
2006-07-20 |
2012-12-25 |
Gilead Sciences, Inc. |
Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
|
BRPI0716604A2
(pt)
*
|
2006-09-08 |
2013-04-09 |
Braincells Inc |
combinaÇÕes contendo um derivado de 4-acilaminopiridina
|
US20080103165A1
(en)
*
|
2006-09-19 |
2008-05-01 |
Braincells, Inc. |
Ppar mediated modulation of neurogenesis
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
JP2010505961A
(ja)
*
|
2006-10-09 |
2010-02-25 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
SG158147A1
(en)
|
2006-10-09 |
2010-01-29 |
Takeda Pharmaceutical |
Kinase inhibitors
|
KR20090071662A
(ko)
*
|
2006-10-21 |
2009-07-01 |
애보트 게엠베하 운트 콤파니 카게 |
헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도
|
WO2008057940A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
|
JP2010513567A
(ja)
*
|
2006-12-19 |
2010-04-30 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼの阻害剤として有用なアミノピリミジン
|
WO2008077650A1
(en)
|
2006-12-26 |
2008-07-03 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
TW200840584A
(en)
|
2006-12-26 |
2008-10-16 |
Gilead Sciences Inc |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
US8143394B2
(en)
|
2006-12-26 |
2012-03-27 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
AU2008213808B2
(en)
|
2007-02-06 |
2011-11-10 |
Novartis Ag |
PI 3-kinase inhibitors and methods of their use
|
WO2008100412A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperidine derivatives
|
EP2121633A2
(de)
*
|
2007-02-12 |
2009-11-25 |
Merck & Co., Inc. |
Piperazinderivate zur behandlung von alzheimer-krankheit und verwandten leiden
|
EP2133095A4
(de)
|
2007-03-05 |
2012-09-26 |
Kyowa Hakko Kirin Co Ltd |
Pharmazeutische zusammensetzung
|
CA2679701A1
(en)
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines useful as inhibitors of protein kinases
|
NZ579446A
(en)
*
|
2007-03-09 |
2012-02-24 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
EP2137183B1
(de)
*
|
2007-03-09 |
2011-09-28 |
Vertex Pharmaceuticals Incorporated |
Als inhibitoren von proteinkinasen geeignete aminopyrimidine
|
NZ580343A
(en)
|
2007-04-13 |
2012-03-30 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
EP2155742A1
(de)
*
|
2007-04-18 |
2010-02-24 |
AstraZeneca AB |
5-aminopyrazol-3-yl-3h-imidazo[4,5-b]pyridinderivate und ihre verwendung zur behandlung von krebs
|
MX2009011810A
(es)
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Tiazoles y pirazoles utiles como inhibidores de cinasa.
|
AU2008247595A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
EP2152696B1
(de)
*
|
2007-05-02 |
2014-09-24 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidine als kinasehemmer
|
US20100137398A1
(en)
*
|
2007-05-04 |
2010-06-03 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
NZ581259A
(en)
|
2007-05-09 |
2012-07-27 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
JP2010528021A
(ja)
*
|
2007-05-24 |
2010-08-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
|
US20090029992A1
(en)
*
|
2007-06-11 |
2009-01-29 |
Agoston Gregory E |
Substituted pyrazole compounds
|
EP2166854A4
(de)
*
|
2007-06-13 |
2012-05-16 |
Merck Sharp & Dohme |
Triazolderivate zur behandlung von morbus alzheimer und verwandten leiden
|
CN101687840A
(zh)
|
2007-06-25 |
2010-03-31 |
霍夫曼-拉罗奇有限公司 |
作为激酶抑制剂的苯并咪唑酰胺基衍生物
|
JP5542282B2
(ja)
*
|
2007-07-05 |
2014-07-09 |
アレイ バイオファーマ、インコーポレイテッド |
Aktプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
ES2551352T3
(es)
|
2007-07-05 |
2015-11-18 |
Array Biopharma, Inc. |
Pirimido ciclopentanos útiles para el tratamiento de enfermedades inflamatorias o hiperproliferativas
|
CN101808693A
(zh)
|
2007-07-25 |
2010-08-18 |
百时美施贵宝公司 |
三嗪激酶抑制剂
|
TW200906818A
(en)
*
|
2007-07-31 |
2009-02-16 |
Astrazeneca Ab |
Chemical compounds
|
CA2694499A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
KR20100088142A
(ko)
*
|
2007-11-20 |
2010-08-06 |
머크 샤프 앤드 돔 코포레이션 |
비-뉴클레오사이드 역전사효소 억제제
|
CA3147290A1
(en)
*
|
2007-12-07 |
2009-06-18 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
KR20150063170A
(ko)
|
2007-12-07 |
2015-06-08 |
버텍스 파마슈티칼스 인코포레이티드 |
3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
|
JP2011032169A
(ja)
*
|
2007-12-11 |
2011-02-17 |
Genecare Research Institute Co Ltd |
4−アミノピリミジン誘導体および該化合物を含有する医薬組成物
|
US8288397B2
(en)
|
2007-12-17 |
2012-10-16 |
Janssen Pharmaceutica Nv |
Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
|
WO2009089454A1
(en)
|
2008-01-09 |
2009-07-16 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
ES2426092T3
(es)
*
|
2008-01-09 |
2013-10-21 |
Array Biopharma, Inc. |
5H-Ciclopenta[d]pirimidinas como inhibidores de proteínas cinasas AKT
|
MX2010009268A
(es)
|
2008-02-21 |
2010-09-14 |
Schering Corp |
Compuestos que son inhibidores de erk.
|
CN102245573B
(zh)
|
2008-02-28 |
2013-11-20 |
沃泰克斯药物股份有限公司 |
作为cftr调节剂的杂芳基衍生物
|
JP2011513483A
(ja)
*
|
2008-03-10 |
2011-04-28 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
|
CL2009000904A1
(es)
*
|
2008-04-21 |
2010-04-30 |
Shionogi & Co |
Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
EA029131B1
(ru)
|
2008-05-21 |
2018-02-28 |
Ариад Фармасьютикалз, Инк. |
Фосфорсодержащие производные в качестве ингибиторов киназы
|
AU2009259026B2
(en)
*
|
2008-06-11 |
2012-10-04 |
Astrazeneca Ab |
Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
|
MX2010013726A
(es)
|
2008-06-12 |
2011-01-14 |
Janssen Pharmaceutica Nv |
Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina.
|
CN102083831B
(zh)
*
|
2008-07-03 |
2014-09-03 |
默克专利有限公司 |
用作aurora激酶抑制剂的萘啶酮
|
WO2010002998A1
(en)
|
2008-07-03 |
2010-01-07 |
Gilead Sciences, Inc. |
2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
|
UA101676C2
(uk)
*
|
2008-07-31 |
2013-04-25 |
Дженентек, Инк. |
Піримідинові сполуки, композиції і способи застосування
|
WO2010019392A1
(en)
*
|
2008-08-13 |
2010-02-18 |
Merck Sharp & Dohme Corp. |
Purine derivatives for treatment of alzheimer's disease
|
EP2323622A1
(de)
*
|
2008-09-03 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Co-kristalle und diese enthaltende pharmazeutische formulierungen
|
CN102264728B
(zh)
*
|
2008-09-15 |
2015-02-04 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
US20110201628A1
(en)
*
|
2008-09-30 |
2011-08-18 |
Astrazeneca Ab |
Heterocyclic jak kinase inhibitors
|
CA2744343A1
(en)
*
|
2008-11-19 |
2010-05-27 |
Renovis, Inc. |
6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof
|
KR101048448B1
(ko)
|
2008-11-21 |
2011-07-11 |
한국화학연구원 |
신규 피라졸로[4,3-b]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
|
ME02337B
(de)
|
2009-02-05 |
2016-06-20 |
Takeda Pharmaceuticals Co |
Pyridazinonverbindungen
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
SI2401267T1
(sl)
*
|
2009-02-27 |
2014-05-30 |
Ambit Biosciences Corporation |
Derivati kinazolina, ki modulirajo JAK-kinazo, in njihova uporaba v postopkih
|
CA2755095A1
(en)
*
|
2009-03-09 |
2010-09-16 |
Surface Logix, Inc. |
Rho kinase inhibitors
|
US8492397B2
(en)
|
2009-03-23 |
2013-07-23 |
Vertex Pharmaceuticals Incorporated |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
EP2411011A4
(de)
*
|
2009-03-24 |
2012-08-15 |
Msd Kk |
Neue aminopyridinderivate mit selektiver aurora-a-hemmung
|
CA2755810A1
(en)
*
|
2009-03-24 |
2010-09-30 |
Msd K.K. |
Novel aminopyridine derivatives having aurora a selective inhibitory action
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
AU2010259002B2
(en)
*
|
2009-06-08 |
2014-03-20 |
Nantbio, Inc. |
Triazine derivatives and their therapeutical applications
|
US20120202818A1
(en)
*
|
2009-06-09 |
2012-08-09 |
California Capital Equity, Llc |
Ureidophenyl substituted triazine derivatives and their therapeutical applications
|
EP2440057A4
(de)
|
2009-06-09 |
2012-12-05 |
California Capital Equity Llc |
Triazinderivate und deren therapeutische anwendungen
|
US20100331305A1
(en)
*
|
2009-06-24 |
2010-12-30 |
Genentech, Inc. |
Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
|
TWI468402B
(zh)
*
|
2009-07-31 |
2015-01-11 |
必治妥美雅史谷比公司 |
降低β-類澱粉生成之化合物
|
US8637525B2
(en)
|
2009-07-31 |
2014-01-28 |
Bristol-Myers Squibb Company |
Compounds for the reduction of beta-amyloid production
|
US20110053916A1
(en)
|
2009-08-14 |
2011-03-03 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine compounds as tuberculosis inhibitors
|
CN102020657A
(zh)
*
|
2009-09-11 |
2011-04-20 |
上海艾力斯医药科技有限公司 |
稠合杂芳基衍生物、制备方法及其应用
|
CA2778686C
(en)
|
2009-11-12 |
2015-07-21 |
F. Hoffmann-La Roche Ag |
N-9-substituted purine compounds, compositions and methods of use
|
EP2499143B1
(de)
|
2009-11-12 |
2016-03-16 |
F.Hoffmann-La Roche Ag |
N7-substituierte purin und pyrazolopyrimidin verbindungen, zusammensetzungen und verfahren zu ihrer verwendung
|
BR112012020273A8
(pt)
|
2010-02-11 |
2017-12-26 |
Univ Vanderbilt |
compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica
|
WO2011127241A2
(en)
|
2010-04-07 |
2011-10-13 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
|
AU2011254550B2
(en)
|
2010-05-21 |
2013-11-07 |
Noviga Research Ab |
Novel pyrimidine derivatives
|
SI2576541T1
(sl)
|
2010-06-04 |
2016-07-29 |
F. Hoffmann-La Roche Ag |
Aminopirimidinski derivati kot modulatorji lrrk2
|
US20110319409A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Cox Christopher D |
7-aza-quinazoline pde10 inhibitors
|
MX2013002384A
(es)
|
2010-09-01 |
2013-07-05 |
Ambit Biosciences Corp |
Compuestos quinazolina y metodos para utilizarlos.
|
US9266855B2
(en)
|
2010-09-27 |
2016-02-23 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
RS59106B1
(sr)
|
2010-11-10 |
2019-09-30 |
Genentech Inc |
Derivati pirazol aminopirimidina kao lrrk2 modulatori
|
CN104906103B
(zh)
|
2010-12-14 |
2018-05-18 |
电泳有限公司 |
酪蛋白激酶1δ(CK1δ)抑制剂
|
WO2012085815A1
(en)
|
2010-12-21 |
2012-06-28 |
Novartis Ag |
Bi-heteroaryl compounds as vps34 inhibitors
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
US9481670B2
(en)
*
|
2011-01-25 |
2016-11-01 |
Sphaera Pharma Pte. Ltd. |
Triazine compounds
|
BR112013024378A2
(pt)
|
2011-03-24 |
2016-12-13 |
Chemilia Ab |
novos derivados de pirimidina
|
EP2694073B1
(de)
|
2011-04-01 |
2018-08-08 |
Genentech, Inc. |
Kombinationen aus akt- und mek-hemmer zur behandlung von krebs
|
AU2012236138A1
(en)
|
2011-04-01 |
2013-11-14 |
Genentech, Inc. |
Combinations of AKT inhibitor compounds and erlotinib, and methods of use
|
RU2477723C2
(ru)
|
2011-06-16 |
2013-03-20 |
Общество С Ограниченной Ответственностью "Фьюжн Фарма" |
Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
US8846656B2
(en)
|
2011-07-22 |
2014-09-30 |
Novartis Ag |
Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
|
CA2844729A1
(en)
|
2011-08-25 |
2013-02-28 |
F. Hoffmann-La Roche Ag |
Serine/threonine pak1 inhibitors
|
RU2627693C2
(ru)
|
2011-09-14 |
2017-08-10 |
СЭМЬЮМЕД, ЭлЭлСи |
ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/b-КАТЕНИНА
|
KR20140059246A
(ko)
|
2011-09-22 |
2014-05-15 |
화이자 인코포레이티드 |
피롤로피리미딘 및 퓨린 유도체
|
CU24269B1
(es)
|
2011-09-27 |
2017-08-08 |
Novartis Ag |
3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
|
CA2854248A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
2,4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
WO2013138613A1
(en)
*
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
WO2013140148A1
(en)
*
|
2012-03-19 |
2013-09-26 |
Imperial Innovations Limited |
Quinazoline compounds and their use in therapy
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
PT2841428T
(pt)
|
2012-04-24 |
2018-11-29 |
Vertex Pharma |
Inibidores de adn-pk
|
CN106279202A
(zh)
*
|
2012-05-03 |
2017-01-04 |
霍夫曼-拉罗奇有限公司 |
作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物
|
CN106220615A
(zh)
*
|
2012-05-03 |
2016-12-14 |
霍夫曼-拉罗奇有限公司 |
作为lrrk2调节剂的吡唑氨基嘧啶衍生物
|
WO2014004376A2
(en)
|
2012-06-26 |
2014-01-03 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
KR102215272B1
(ko)
*
|
2012-09-28 |
2021-02-15 |
이그니타, 인코포레이티드 |
비정형 단백질 키나제 c의 아자퀴나졸린 억제제
|
JO3470B1
(ar)
|
2012-10-08 |
2020-07-05 |
Merck Sharp & Dohme |
مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
|
DK2909181T3
(da)
*
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
WO2014081718A1
(en)
*
|
2012-11-20 |
2014-05-30 |
Genentech, Inc. |
Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
|
KR102275676B1
(ko)
|
2012-11-21 |
2021-07-12 |
피티씨 테라퓨틱스, 인크. |
치환된 리버스 피리미딘 bmi-1 저해제
|
CN103012428A
(zh)
|
2013-01-08 |
2013-04-03 |
中国药科大学 |
4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
|
WO2014110086A2
(en)
|
2013-01-08 |
2014-07-17 |
Samumed, Llc |
3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
|
EP2951170B1
(de)
|
2013-02-04 |
2018-10-24 |
Janssen Pharmaceutica NV |
Flap-modulatoren
|
TWI644899B
(zh)
|
2013-02-04 |
2018-12-21 |
健生藥品公司 |
Flap調節劑
|
EP2769722A1
(de)
*
|
2013-02-22 |
2014-08-27 |
Ruprecht-Karls-Universität Heidelberg |
Verbindungen zur Verwendung bei der Hemmung einer HIV-Kapsid-Anordnung
|
JO3377B1
(ar)
*
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
US9340557B2
(en)
|
2013-03-12 |
2016-05-17 |
Vertex Pharmaceuticals Incorporated |
Substituted quinoxaline DNA-PK inhibitors
|
EA028033B1
(ru)
|
2013-03-14 |
2017-09-29 |
Новартис Аг |
3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
|
JP6360881B2
(ja)
|
2013-03-22 |
2018-07-18 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ
|
CA2928568A1
(en)
|
2013-07-26 |
2015-01-29 |
Update Pharma Inc. |
Combinatorial methods to improve the therapeutic benefit of bisantrene
|
EP3039015B1
(de)
|
2013-08-30 |
2019-10-30 |
PTC Therapeutics, Inc. |
Substituierte pyrimidin-bmi-1 inhibitoren
|
WO2015028848A1
(en)
*
|
2013-09-02 |
2015-03-05 |
Piramal Enterprises Limited |
Bicyclic heterocyclic compounds as multi-kinase inhibitors
|
EA032196B1
(ru)
|
2013-10-03 |
2019-04-30 |
Кура Онколоджи, Инк. |
Ингибиторы erk и способы применения
|
CN104903312B
(zh)
|
2013-10-07 |
2019-01-29 |
卡德门企业有限公司 |
Rho激酶抑制剂
|
LT3424920T
(lt)
|
2013-10-17 |
2020-08-10 |
Vertex Pharmaceuticals Incorporated |
(s)-n-metil-8-(1-((2`-metil-[4,5`-bipirimidin]-6-il)amino)propan-2-il)chinolin-4-karboksamido ir jo deuterintų darinių, kaip dnr-pk inhibitorių, bendri kristalai
|
NZ720958A
(en)
|
2013-11-12 |
2022-02-25 |
Vertex Pharma |
Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
|
US9975878B2
(en)
|
2013-11-21 |
2018-05-22 |
Ptc Therapeutics, Inc. |
Substituted triazine BMI-1 inhibitors
|
EP3071553A4
(de)
*
|
2013-11-21 |
2017-08-02 |
PTC Therapeutics, Inc. |
Substituierte pyridin- und pyrazin-bmi-1-hemmer
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN104672250B
(zh)
*
|
2013-11-29 |
2017-11-07 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
CN109045032A
(zh)
|
2014-01-01 |
2018-12-21 |
麦迪威森技术有限责任公司 |
氨基吡啶类化合物和使用方法
|
WO2015112739A1
(en)
*
|
2014-01-22 |
2015-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds and method for treating parp1-deficient cancers
|
CN104926795B
(zh)
*
|
2014-03-17 |
2017-11-10 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
TWI675836B
(zh)
*
|
2014-03-25 |
2019-11-01 |
美商伊格尼塔公司 |
非典型蛋白質激酶c之氮雜喹唑啉抑制劑
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
CN105367555B
(zh)
*
|
2014-08-07 |
2019-06-25 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
BR112017010406B1
(pt)
|
2014-11-18 |
2021-03-09 |
Vertex Pharmaceuticals Incorporated |
processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
|
TWI704151B
(zh)
*
|
2014-12-22 |
2020-09-11 |
美商美國禮來大藥廠 |
Erk抑制劑
|
US9879029B2
(en)
*
|
2014-12-22 |
2018-01-30 |
Eli Lilly And Company |
ERK inhibitors
|
US10227343B2
(en)
|
2015-01-30 |
2019-03-12 |
Vanderbilt University |
Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
EP3070084A1
(de)
*
|
2015-03-18 |
2016-09-21 |
Rottapharm Biotech S.r.l. |
Neue fyn-kinase-inhibitoren
|
US10752612B2
(en)
|
2015-04-17 |
2020-08-25 |
Ludwig Institute For Cancer Research Ltd |
PLK4 inhibitors
|
CA2988306A1
(en)
|
2015-06-05 |
2016-12-08 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017024025A1
(en)
|
2015-08-03 |
2017-02-09 |
Sunil Kumar Kc |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024015A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023975A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023996A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
US10226453B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023988A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024026A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023980A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017024021A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10544139B2
(en)
|
2015-11-06 |
2020-01-28 |
Samumed, Llc |
Treatment of osteoarthritis
|
GB201604647D0
(en)
*
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
KR20190062485A
(ko)
|
2016-09-27 |
2019-06-05 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
|
JP2019535672A
(ja)
|
2016-10-21 |
2019-12-12 |
サミュメッド リミテッド ライアビリティ カンパニー |
インダゾール−3−カルボキサミドの使用方法およびwnt/β−カテニンシグナル伝達経路阻害剤としてのそれらの使用
|
EP3534888B1
(de)
*
|
2016-11-01 |
2022-04-06 |
Merck Sharp & Dohme Corp. |
Substituierte bicyclische heteroaryl-allosterische modulatoren von nikotinischen acetylcholin-rezeptoren
|
US10758523B2
(en)
|
2016-11-07 |
2020-09-01 |
Samumed, Llc |
Single-dose, ready-to-use injectable formulations
|
IT201700047189A1
(it)
*
|
2017-05-02 |
2018-11-02 |
Fondazione St Italiano Tecnologia |
Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
|
AR112027A1
(es)
*
|
2017-06-15 |
2019-09-11 |
Biocryst Pharm Inc |
Inhibidores de alk 2 quinasa que contienen imidazol
|
CN110582491B
(zh)
|
2017-06-30 |
2023-09-29 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
JP7311228B2
(ja)
|
2017-06-30 |
2023-07-19 |
ベイジン タイド ファーマシューティカル カンパニー リミテッド |
Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
|
KR102563325B1
(ko)
*
|
2017-06-30 |
2023-08-03 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
Rho-관련 단백질 키나아제 억제제, Rho-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
|
CN109384774B
(zh)
*
|
2017-08-11 |
2023-02-17 |
中国科学院上海药物研究所 |
一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
|
US10308646B2
(en)
|
2017-10-27 |
2019-06-04 |
Theravance Biopharma R&D Ip, Llc |
Pyrimidine compound as JAK kinase inhibitor
|
GB201801226D0
(en)
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
WO2020005935A1
(en)
*
|
2018-06-25 |
2020-01-02 |
Kadmon Corporation, Llc |
Glucose uptake inhibitors
|
KR102328682B1
(ko)
*
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
WO2020045941A1
(ko)
*
|
2018-08-27 |
2020-03-05 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
DK3902803T3
(da)
|
2018-12-27 |
2023-02-13 |
Servier Lab |
Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
|
KR20210111787A
(ko)
|
2019-01-03 |
2021-09-13 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
전사 인자 eb 폴리펩티드 수준을 증가시키기 위한 방법 및 물질
|
WO2020163812A1
(en)
|
2019-02-08 |
2020-08-13 |
Frequency Therapeutics, Inc. |
Valproic acid compounds and wnt agonists for treating ear disorders
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
EP3941463A1
(de)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Zusammensetzungen mit pkm2-modulatoren und behandlungsverfahren damit
|
TW202102511A
(zh)
|
2019-03-28 |
2021-01-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
CN113544131B
(zh)
|
2019-03-29 |
2024-03-15 |
江苏恒瑞医药股份有限公司 |
吡咯并杂环类衍生物、其制备方法及其在医药上的应用
|
CN109826608A
(zh)
*
|
2019-04-08 |
2019-05-31 |
中国科学院地质与地球物理研究所 |
一种分段压裂装置
|
AR118768A1
(es)
|
2019-04-24 |
2021-10-27 |
Theravance Biopharma R&D Ip Llc |
Derivados de pirimidina como inhibidores de las cinasas jak
|
WO2020219640A1
(en)
|
2019-04-24 |
2020-10-29 |
Theravance Biopharma R&D Ip, Llc |
Pyrimidine jak inhibitors for the treatment of skin diseases
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
EP3978498A1
(de)
|
2019-05-24 |
2022-04-06 |
Jiangsu Hengrui Medicine Co., Ltd. |
Substituierte kondensierte bicyclische derivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
|
MA56047A
(fr)
*
|
2019-05-29 |
2022-04-06 |
Ifm Due Inc |
Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
|
CN116348458A
(zh)
|
2019-08-14 |
2023-06-27 |
因赛特公司 |
作为cdk2抑制剂的咪唑基嘧啶基胺化合物
|
WO2021043966A1
(en)
*
|
2019-09-06 |
2021-03-11 |
Inflazome Limited |
Nlrp3 inhibitors
|
EP4041399A1
(de)
*
|
2019-10-02 |
2022-08-17 |
Tolremo Therapeutics AG |
Heterocyclische derivate, pharmazeutische zusammensetzungen und deren verwendung zur behandlung oder linderung von krebs
|
BR112022006977A2
(pt)
|
2019-10-11 |
2022-09-20 |
Incyte Corp |
Aminas bicíclicas como inibidores de cdk2
|
WO2021173082A1
(en)
*
|
2020-02-26 |
2021-09-02 |
Jaguahr Therapeutics Pte Ltd |
Pyridopyrimidine derivatives useful in modulation of ahr signalling
|
JP2023533849A
(ja)
|
2020-07-15 |
2023-08-04 |
キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ |
Alk5阻害剤としてのピリダジニルアミノ誘導体
|
WO2022032484A1
(zh)
*
|
2020-08-11 |
2022-02-17 |
北京诺诚健华医药科技有限公司 |
哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
|
TW202221001A
(zh)
|
2020-09-29 |
2022-06-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
吡咯並雜環類衍生物的晶型及其製備方法
|
WO2022107919A1
(ko)
*
|
2020-11-19 |
2022-05-27 |
주식회사 보로노이 |
N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
|
TW202317574A
(zh)
|
2021-06-28 |
2023-05-01 |
美商纜圖藥品公司 |
Cdk2抑制劑
|
WO2023046698A1
(en)
|
2021-09-21 |
2023-03-30 |
Chiesi Farmaceutici S.P.A. |
Pyridazinyl amino derivatives as alk5 inhibitors
|
CN116023380B
(zh)
*
|
2021-10-26 |
2024-01-23 |
沈阳药科大学 |
一类吡唑并嘧啶衍生物及制备方法和应用
|
WO2023135107A1
(en)
|
2022-01-11 |
2023-07-20 |
Chiesi Farmaceutici S.P.A. |
Pyridazinyl amino derivatives as alk5 inhibitors
|